CD274 and neoplasm: The use of PD-L1 IHC as a predictive marker is confounded by multiple unresolved issues including variable detection antibodies, differing IHC cutoffs, tissue preparation, processing variability, primary versus metastatic biopsies, oncogenic versus induced PD-L1 expression, and staining of tumor versus immune cells [106].